✦ Free PDF Download of Your Custom Analysis With Actionable Solutions After Token Purchase ✦
Token-based platform — single use from $1.99 · Pro packages available
SAMPLE ONLY
Medical Appeal — Tirzepatide (Mounjaro) · UnitedHealthcare · FL
PRISM® ANALYSIS REPORT · APPEALS VARIANT · SAMPLE OUTPUT · March 2026
Requested Service
Tirzepatide (Mounjaro) 5mg weekly subcutaneous injection — PA #PA-2026-00287541
Diagnosis
Type 2 Diabetes Mellitus (E11.9), Obesity (E66.09)
Comorbidities
Hypertension (I10), Hyperlipidemia (E78.5), BMI 39.2, A1C 9.6%
Treatments Attempted
Metformin 2000mg — GI intolerance, discontinued after 4 months; Empagliflozin 10mg — 5 months, A1C unchanged at 9.4%; Glipizide 10mg — 6 months, A1C 9.6%, therapeutic failure
Denial Reason
Step therapy criteria not met — plan requires additional tier agent trial prior to dual GIP/GLP-1 agonist approval
Recommended Action
File Level 1 formal appeal with complete step-therapy failure documentation and endocrinologist medical necessity letter citing three documented agent failures
UnitedHealthcare denied prior authorization for tirzepatide (Mounjaro) 5mg weekly for a 52-year-old patient with Type 2 Diabetes Mellitus (E11.9), Class II obesity (BMI 39.2), hypertension, and hyperlipidemia. The stated denial reason is that step therapy criteria have not been met — specifically, UHC's criteria engine flagged the submission as not satisfying its required tier sequence for dual GIP/GLP-1 receptor agonists.
This denial is procedural, not clinical. The patient has documented failure of three sequential agents: metformin (GI intolerance, 4 months), empagliflozin (SGLT-2 inhibitor, therapeutic failure, 5 months), and glipizide (sulfonylurea, therapeutic failure, 6 months). The clinical case for tirzepatide is strong — the denial is a documentation presentation issue and a payer criteria mapping issue, both of which are directly addressable on appeal.
SAMPLE LETTER — FORMAL LEVEL 1 APPEAL
[PRACTICE LETTERHEAD]
[DATE]
To: UnitedHealthcare Prior Authorization Appeals Department
Re: Formal Level 1 Appeal — Denial of Prior Authorization for Tirzepatide (Mounjaro) 5mg Weekly
Auth #: PA-2026-00287541
Patient: [REQUIRED: Patient full legal name]
Date of Birth: [REQUIRED]
Member ID: [REQUIRED: UHC member ID from insurance card]
To the UnitedHealthcare Prior Authorization Appeals Department,
This letter constitutes a formal first-level appeal of UnitedHealthcare's denial of prior authorization PA-2026-00287541 for tirzepatide (Mounjaro) 5mg weekly subcutaneous injection. The denial was issued on the basis that step therapy criteria have not been met. This appeal respectfully disputes that determination and provides documented clinical evidence establishing that the required step-therapy sequence has been completed across three agents, and that tirzepatide is the evidence-based, guideline-concordant next-line intervention for this patient's specific clinical profile.
STEP-THERAPY COMPLIANCE DOCUMENTATION
Agent 1: Metformin 2000mg daily
â–¸ Duration: 4 months
â–¸ Outcome: Discontinued due to clinically significant GI intolerance
▸ Documentation: [REQUIRED: chart note specifying symptoms — nausea, diarrhea, abdominal cramping — and clinical decision to discontinue]
Agent 2: Empagliflozin (Jardiance) 10mg daily — SGLT-2 Inhibitor
â–¸ Duration: 5 months
▸ Outcome: Therapeutic failure — A1C remained at 9.4% at end of trial period
â–¸ Documentation: [REQUIRED: dated lab report showing A1C 9.4% during/after empagliflozin trial]
Agent 3: Glipizide 10mg daily — Sulfonylurea
â–¸ Duration: 6 months
▸ Outcome: Therapeutic failure — A1C 9.6% at end of trial; no meaningful glycemic reduction achieved
â–¸ Documentation: [REQUIRED: dated lab report showing A1C 9.6% during/after glipizide trial]
MEDICAL NECESSITY JUSTIFICATION
Tirzepatide (Mounjaro) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, FDA-approved for Type 2 Diabetes Mellitus. Its dual mechanism of action produces significantly greater A1C reduction and weight loss than either GLP-1 monotherapy or any prior-line agent this patient has trialed.
This patient's current A1C of 9.6% following three documented sequential failures represents clinically unacceptable glycemic dyscontrol. The combination of Class II obesity (BMI 39.2), hypertension, and hyperlipidemia creates a cardiometabolic risk profile for which tirzepatide's dual mechanism addresses multiple risk dimensions simultaneously. No adequately documented alternative agent achieves this in this patient's specific clinical context.
Per the American Diabetes Association (ADA) Standards of Care, patients with T2DM who have not achieved glycemic targets following multiple agent failures, and who have obesity and cardiovascular risk factors, should be considered for advanced pharmacotherapy with proven cardiometabolic benefit. Tirzepatide is FDA-approved for this indication and is consistent with current ADA and AACE guidelines.
We respectfully request immediate approval of tirzepatide (Mounjaro) 5mg weekly for this patient.
Sincerely,
[REQUIRED: Prescribing physician full name, credentials, NPI, practice, signature]
RECOMMENDED DOCUMENTATION CHECKLIST
Chart note documenting metformin GI intolerance with specific symptoms
→ "Patient experienced [nausea / diarrhea / abdominal cramping] on metformin 2000mg daily. Symptoms were persistent and clinically significant. Metformin was discontinued after 4 months."
REQUIRED
Dated lab report showing A1C 9.4% during/after empagliflozin trial
→ Must display: patient name, date of collection, result (9.4%), performing lab. This is your SGLT-2 failure evidence — critical for UHC's criteria engine.
REQUIRED
Dated lab report showing A1C 9.6% during/after glipizide trial
→ "Patient trialed glipizide 10mg daily for 6 months. A1C remained at 9.6% — inadequate glycemic control. Therapy deemed a therapeutic failure."
REQUIRED
All three agents listed in the structured step-therapy section of the appeal form — not just the narrative
→ Metformin, empagliflozin, and glipizide must each appear on the structured form with drug name, dose, duration, and outcome. Narrative-only is a common denial trigger.
REQUIRED
Signed Letter of Medical Necessity from prescribing endocrinologist
→ Specialty prescriber attestation carries elevated evidentiary weight in UHC PA appeals. Letter must address each step-therapy element and the clinical rationale for tirzepatide specifically.
REQUIRED
BMI documentation and current vital signs
→ BMI 39.2 and most recent BP reading in clinical note. Obesity documentation strengthens the tirzepatide-specific argument — its dual mechanism is guideline-preferred for patients with BMI ≥35.
RECOMMENDED
DPP-4 inhibitor clinical rationale — address proactively if not trialed
→ If UHC's criteria require a DPP-4 trial: "DPP-4 inhibitor class produces a mean A1C reduction of 0.5–0.8% — insufficient for a patient with A1C 9.6% requiring substantial reduction."
RECOMMENDED
| Criterion | Documentation Provided | Status |
|---|
| FDA-approved indication (T2DM) | E11.9 confirmed; tirzepatide FDA-approved for T2DM | ✓ MET |
| Diagnosis confirmed with objective data | HbA1c 9.6% documented across multiple trials | ✓ MET |
| Prescriber specialty appropriate | Endocrinology — specialty prescriber | ✓ MET |
| Metformin trial — documented failure | Metformin 2000mg × 4 months, GI intolerance | ⚠PARTIAL — requires chart note with specific symptoms |
| SGLT-2 inhibitor trial — documented failure | Empagliflozin 10mg × 5 months, A1C 9.4% | ⚠PARTIAL — requires dated lab report |
| Sulfonylurea trial — documented failure | Glipizide 10mg × 6 months, A1C 9.6% | ⚠PARTIAL — requires dated lab report |
| DPP-4 inhibitor trial [VERIFY WITH PAYER] | Not documented in intake | ✗ GAP — confirm with UHC current policy |
| A1C threshold for advanced therapy | A1C 9.6% — exceeds typical commercial threshold | ✓ MET |
| BMI / obesity documentation | BMI 39.2 documented | ✓ MET |
| Cardiovascular risk documentation | Hypertension and hyperlipidemia documented | ✓ MET |
| Signed Letter of Medical Necessity | LMN generated — requires physician signature | ⚠PARTIAL — requires signed LMN |
Florida Statutes §627.64741 — Step Therapy Override
Florida law gives patients the right to request a step therapy exception when they have already tried and failed required step agents, or when step therapy is clinically contraindicated. Three documented failures — metformin, empagliflozin, and glipizide — constitute a strong step therapy override basis. Applies to fully insured commercial plans only. Confirm ERISA status before citing state law.
ADA Standards of Care in Diabetes (Current Annual Edition)
Recommends individualized pharmacotherapy escalation when glycemic targets are not met on current regimen. Supports GIP/GLP-1 dual agonist use in patients with T2DM, obesity (BMI ≥35), and cardiovascular risk factors. Tirzepatide demonstrated superior A1C reduction and weight loss vs. semaglutide in the SURPASS-2 trial. Cite current edition year at time of submission.
SURPASS-2 Trial (FrÃas et al., NEJM 2021)
Tirzepatide demonstrated statistically significant superiority over semaglutide 1mg in A1C reduction and weight loss in patients with T2DM. At the 15mg dose, mean A1C reduction was 2.46% vs. 1.86% for semaglutide. This trial supports tirzepatide as the preferred agent for patients with high baseline A1C and obesity who have failed prior GLP-1 class agents or require maximum glycemic reduction.
ERISA Status Advisory
If this is a self-funded ERISA plan, Florida insurance statutes governing PA timelines and step therapy overrides may not be enforceable. Federal ERISA claims procedures govern. Confirm plan funding type from the insurance card or HR department before citing state law in a formal appeal.
DECISION LOGIC IDENTIFIED
UnitedHealthcare's prior authorization criteria for dual GIP/GLP-1 receptor agonists (tirzepatide) apply a more stringent step therapy framework than standard GLP-1 criteria, reflecting tirzepatide's position as a newer, higher-cost agent class. UHC's criteria engine evaluates each submitted step sequentially and may require documentation of specific agent classes in a specific order.
The denial language — "step therapy criteria not met" — does not specify which step was flagged. This is intentional. UHC's criteria engine generates this language when any required step is absent or insufficiently documented, regardless of how many steps were actually completed.
The three documented failures in this submission (metformin, SGLT-2 inhibitor, sulfonylurea) represent a strong step-therapy compliance record. The most likely denial trigger is either: (1) the empagliflozin or glipizide trials not appearing in the structured PA form fields, or (2) UHC's criteria requiring a DPP-4 inhibitor trial that was not documented. Both are addressable on appeal.
MISSING INFORMATION OR CRITERIA
▸ DPP-4 inhibitor trial — Not documented. UHC's tirzepatide criteria may require a DPP-4 inhibitor (e.g., sitagliptin, saxagliptin) trial in addition to SGLT-2 and sulfonylurea documentation. Verify with UHC's current Clinical Policy Bulletin for tirzepatide before submitting the appeal. If required, prepare a clinical exception argument citing A1C 9.6% — DPP-4 inhibitors produce insufficient A1C reduction (0.5–0.8%) for this patient.
▸ Structured form completeness — All three agents (metformin, empagliflozin, glipizide) must appear in the structured step-therapy fields on the appeal form, not only in the narrative letter. Confirm the appeal submission form includes all three entries with drug name, dose, duration, and outcome.
▸ Dated lab reports not yet attached — The A1C values for each trial are referenced in the submission but dated lab reports must be physically attached. Without dates, the payer cannot confirm adequate trial duration.
MOST LIKELY SUCCESSFUL NEXT STEP
Call UHC Provider Services before submitting the appeal and ask: "Does your current clinical policy bulletin for tirzepatide (Mounjaro) require a DPP-4 inhibitor trial in addition to SGLT-2 and sulfonylurea documentation for this patient's plan?" Document the rep name and call date.
If DPP-4 is not required: submit the complete appeal package with the three documented failures, all structured form fields populated, dated lab reports attached, and signed LMN.
If DPP-4 is required: add a physician attestation letter explaining why a DPP-4 trial is clinically inappropriate — citing A1C 9.6% (DPP-4 class produces insufficient reduction for this level), BMI 39.2, and the clinical preference for tirzepatide's dual mechanism in this metabolic profile. Cite Florida's step therapy override statute if on a fully insured commercial plan.
OPTION 1 · Peer-to-Peer Call with UHC Medical Director
The prescribing endocrinologist can request a peer-to-peer (P2P) call with UHC's medical director. P2P calls resolve GLP-1 and dual agonist denials at significantly higher rates when the prescriber can present three documented failures directly. Request the P2P simultaneously with or immediately after filing the written appeal — do not wait for the written appeal decision.
OPTION 2 · Mounjaro Savings Card / Eli Lilly Patient Support
Eli Lilly's Mounjaro Savings Program may reduce out-of-pocket cost significantly for commercially insured patients while the appeal is pending. The Lilly Cares Foundation also offers patient assistance for eligible patients. The prescriber's office can initiate the application. Do not delay treatment while awaiting appeal resolution if the patient can access the medication through manufacturer support.
OPTION 3 · External Independent Medical Review (Florida)
If Level 1 appeal is denied, file for an Independent Medical Review through the Florida Department of Insurance (fully insured commercial plans only). IMR decisions are legally binding on UHC. Tirzepatide denials with three documented step-therapy failures and an A1C of 9.6% present a strong IMR case — the clinical evidence substantially supports medical necessity.
Level 1 — Formal Written Appeal (now)
File within the deadline stated on the denial letter. Include the complete documentation package, structured form with all three step-therapy entries, dated lab reports, and signed LMN. Request that the appeal be reviewed by a physician in endocrinology or internal medicine.
Level 2 — Peer-to-Peer Call
Request simultaneously with the written appeal. The endocrinologist should be prepared to discuss each step-therapy failure and the specific clinical rationale for tirzepatide over alternative agents, with reference to the SURPASS-2 trial data.
Level 3 — External IMR / Florida DOI Complaint
If Level 1 is denied: file for Independent Medical Review through the Florida Department of Insurance. Simultaneously, file a complaint with the Florida Office of Insurance Regulation (OIR) if the appeal process is delayed or handled in bad faith. OIR complaints create a regulatory record and frequently accelerate internal resolution.
Level 4 — Legal Consultation
If three documented step-therapy failures with an A1C of 9.6% does not result in approval, consult a licensed insurance attorney. A denial under these clinical circumstances may give rise to bad faith considerations depending on the plan type and applicable state law.
This case is navigable — and the clinical record is unusually strong. Three documented sequential failures across three different agent classes (biguanide, SGLT-2 inhibitor, sulfonylurea), an A1C of 9.6%, Class II obesity, and a specialty prescriber creates one of the stronger tirzepatide appeal profiles PRISM maps.
The denial is procedural. UHC's criteria engine flagged a documentation gap — not a clinical deficiency. The prescribing endocrinologist has the clinical record to win this appeal. The path is clear: verify the DPP-4 requirement, populate the structured form correctly, attach the dated labs, get the LMN signed. Execute in order and this appeal has a high probability of success.
Call UHC Provider Services and verify whether a DPP-4 inhibitor trial is required — document rep name and call date
Populate all three step-therapy agents (metformin, empagliflozin, glipizide) in the structured fields on the appeal form — not narrative only
Attach dated lab report showing A1C 9.4% during/after empagliflozin trial
Attach dated lab report showing A1C 9.6% during/after glipizide trial
Attach chart note documenting metformin GI intolerance with specific symptom notation
Obtain physician signature on Letter of Medical Necessity before submission
Request peer-to-peer call with UHC medical director simultaneously with written appeal submission
If DPP-4 is required: prepare clinical exception letter citing A1C 9.6%, BMI 39.2, and Florida step therapy override statute
Check denial letter for appeal deadline — do not miss it
Contact Eli Lilly Mounjaro patient support for interim medication access while appeal is pending
